News & Perspective

The announcement comes as Nigeria is experiencing its largest outbreak, with 481 confirmed cases reported as of last week, 133 of them fatal.

The $170.2 million in BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of two Ebola drugs.

Though global risk remains low, 7 countries have begun screening at airports and ports of entry.

Lessons learned can improve Zika response and US readiness for the next threat, experts said.

The Obama administration, though, is sticking with its $1.9 billion request, some of which would cover the shift.

In other developments, the HHS announced more funding for a rapid Ebola test.

The contract is for bolstering monoclonal antibody treatment for Ebola.

As cases drop slightly, vaccine trials suffer from lack of patients. Also, the NIH announces a trial involving survivors.

Funding will be used to continue trials of BCX4430 and prepare for its large-scale manufacture.

UN funding is needed to cover its response activities in the region through 2015, with an urgent need to ramp up before the rainy season.